Stay updated on Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.

Latest updates to the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe website revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check22 days agoChange DetectedLayout/UI updates were observed on the Study Details page. Core study information such as eligibility criteria, outcomes, and locations remains unchanged.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 in the page footer, representing a minor version bump with no other visible changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page shows revision history updated from v3.4.0 to v3.4.1, with no visible changes to study details, layout, or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check88 days agoChange DetectedThe Locations section now lists a large set of new site locations across the United States, Canada, the United Kingdom, Australia, India, and other regions, replacing the prior shorter listing with a more expansive directory. This broadens where the study is conducted and how potential participants can locate a site.SummaryDifference2%

Stay in the know with updates to Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.